Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546454 | 1.00 | KLKB1 (0.37) | KLKB1CFDALDH1A1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL18546403 | 0.99 | KLKB1 (0.36) | KLKB1CFDALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL18611089 | 0.93 | CFD (0.34) | KLKB1CFDALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL18572911 | 0.86 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL18576410 | 0.86 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17034800 | 0.86 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL18548455 | 0.85 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL29545426 | 0.85 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL17047384 | 0.85 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL17023486 | 0.85 | CFD (0.40) | KLKB1CFDALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | KLKB1 348/4885CFD 1/4885ALDH1A1 4280/4885 |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | KLKB1 450/4885CFD 1/4885ALDH1A1 1682/4885 |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | CFD, TFPI, CFH | KLKB1 348/4885CFD 1/4885ALDH1A1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.